Moreover, in genetically predisposed populations, such as those with a family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, tirzepatide might further elevate thyroid cancer risk through GIP-mediated pathways [148]. This evidence concerns the gene GIP and medullary thyroid gland carcinoma.